Tag: 200-300

On April 16, 2021, Xu, Changming; Qi, Yinsheng; Yang, Xinshuang; Li, Xiangfan; Li, Zhenpeng; Bai, Lei published an article.Safety of 4-(Bromomethyl)-1,1′-biphenyl The title of the article was Development of C2-Symmetric Chiral Spirocyclic Phase-Transfer Catalysts: Synthesis and Application to Asymmetric Alkylation of Glycinate Schiff Base. And the article contained the following:

A class of C2-sym. chiral spirocyclic phase-transfer catalysts based on the tetramethyl-1,1′-spirobiindane scaffold such as I·Br- was synthesized from com. available bisphenol A in 12 steps in 22-25% total yields; the scaffold features a more rigid and stable backbone and smaller dihedral angles and can be easily modified. These catalysts show high catalytic performance in the asym. alkylation of tert-Bu glycinate Schiff base Ph2C:NCH2CO2t-Bu at only 2 mol % catalyst loading, giving nonracemic protected α-amino acid esters such as (R)-Ph2C:NCH(CH2Ph)CO2t-Bu in up to 92% yield and 98% ee. The experimental process involved the reaction of 4-(Bromomethyl)-1,1′-biphenyl(cas: 2567-29-5).Safety of 4-(Bromomethyl)-1,1′-biphenyl

The Article related to spirobiindanoazocinium nonracemic preparation catalyst enantioselective phase transfer alkylation, diphenylmethyleneamino ester enantioselective preparation, nonracemic spirobiindanoazocinium bromide enantioselective phase transfer alkylation catalyst, alkyl bromide enantioselective alkylation diphenylmethyleneamino ester spirobiindanoazocinium catalyst and other aspects.Safety of 4-(Bromomethyl)-1,1′-biphenyl

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

Oliver, Martin; Le Corre, Laurent; Poinsot, Melanie; Corio, Alessandra; Madegard, Lea; Bosco, Michael; Amoroso, Ana; Joris, Bernard; Auger, Rodolphe; Touze, Thierry; Bouhss, Ahmed; Calvet-Vitale, Sandrine; Gravier-Pelletier, Christine published an article in 2021, the title of the article was Synthesis, biological evaluation and molecular modeling of urea-containing MraY inhibitors.Computed Properties of 574-98-1 And the article contains the following content:

The straightforward synthesis of aminoribosyl uridines substituted by a 5′-methylene-urea is described. 90Their convergent synthesis involves the urea formation from various activated amides and an azidoribosyl uridine substituted at the 5′ position by an aminomethyl group. This common intermediate resulted from the diastereoselective glycosylation of a phthalimido uridine derivative with a ribosyl fluoride as a ribosyl donor. The inhibition of the MraY transferase activity by the synthesized 11 urea-containing inhibitors was evaluated and 10 compounds revealed MraY inhibition with IC50 ranging from 1.9μM to 16.7μM. Their antibacterial activity was also evaluated on a panel of Gram-pos. and Gram-neg. bacteria. Four compounds exhibited a good activity against Gram-pos. bacterial pathogens with MIC ranging from 8 to 32μg mL-1, including methicillin resistant Staphylococcus aureus (MRSA) and Enterococcus faecium. Interestingly, one compound also revealed antibacterial activity against Pseudomonas aeruginosa with MIC equal to 64μg mL-1. Docking experiments predicted two modes of positioning of the active compounds urea chain in different hydrophobic areas (HS2 and HS4) within the MraY active site from Aquifex aeolicus. However, mol. dynamics simulations showed that the urea chain adopts a binding mode similar to that observed in 5CKR structural model and targets the hydrophobic area HS2. The experimental process involved the reaction of 2-(2-Bromoethyl)isoindoline-1,3-dione(cas: 574-98-1).Computed Properties of 574-98-1

The Article related to stereoselective glycosylation nucleoside mol modeling enzyme active site, methicillin drug resistant staphylococcus aureus enterococcus faecium hydrogen bond, peptide mol modeling urea mray antibacterial enzyme active site, mol modeling inhibitor mray inhibitor synthesis antibacterial transferase phosphoacetylmuramoylpeptidetransferase and other aspects.Computed Properties of 574-98-1

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On May 6, 1999, Thompson, Mervyn; Harling, John David; Edwards, Peter David published a patent.Product Details of 90326-61-7 The title of the patent was Preparation of substituted isoquinolines as anticonvulsants. And the patent contained the following:

The title compounds [I; n, p = 1-4 and n + p = 2-5; R1 = H, cycloalkylO, etc.; R2 = H, halo, CN, etc.; R3 = H, halo, NO2, etc.; R2R3 = (un)substituted (un)saturated carbocyclic ring; R4 = H, alkyl, alkenyl, etc.], useful as anticonvulsants, were prepared Thus, conversion of 2-ethoxy-4-isopropyl-5-cyanobenzoic acid into the acid chloride followed by coupling with 5-amino-2-methyl-1,2,3,4-tetrahydroisoquinoline afforded 60% II.HCl which showed a 336% increase in seizure threshold for rat MEST. Compounds I are useful in the prophylaxis and treatment of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid hemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alc. and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson’s disease, psychosis, migraine, cerebral ischemia, Alzheimer’s disease and other degenerative diseases such as Huntington’s chorea, schizophrenia, obsessive compulsive disorders (OCD), neurol. deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia and narcolepsy), tics (e.g. Giles de la Tourette’s syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neuron disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction and amyotrophic lateral sclerosis (ALS). The experimental process involved the reaction of 5-Bromo-2-methoxy-4-methylbenzoic acid(cas: 90326-61-7).Product Details of 90326-61-7

The Article related to isoquinoline preparation anticonvulsant, anxiolytic isoquinoline preparation, antidepressant isoquinoline preparation, substance abuse isoquinoline preparation, parkinson disease isoquinoline preparation, alzheimer disease isoquinoline preparation, antipsychotic isoquinoline preparation, huntington chorea isoquinoline preparation and other aspects.Product Details of 90326-61-7

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

Miranda, Alexandre S.; Marcos, Paula M.; Ascenso, Jose R.; Robalo, M. Paula; Bonifacio, Vasco D. B.; Berberan-Santos, Mario N.; Hickey, Neal; Geremia, Silvano published an article in 2021, the title of the article was Conventional vs. microwave- or mechanically-assisted synthesis of dihomooxacalix[4]arene phthalimides: NMR, X-ray and photophysical analysis.Product Details of 574-98-1 And the article contains the following content:

Direct O-alkylation of p-tert-Bu dihomooxacalix[4]arene with N-(bromopropyl)- or N-(bromoethyl)phthalimides and K2CO3 in acetonitrile were conducted under conventional heating (reflux) and using microwave irradiation and ball milling methodologies. The reactions afforded mono- and mainly distal di-substituted derivatives in the cone conformation, in a total of eight compounds I [Y1=Y2=Y3=Y4 = H, phthalimidoethyl, phthalimidopropyl]. The compounds I were isolated by column chromatog., and their conformations and the substitution patterns were established by NMR spectroscopy (1H, 13C, COSY and NOESY experiments). The X-ray structures of four dihomooxacalix[4]arene phthalimide derivatives I[Y1=Y2=Y3 = H, Y4 = phthalimidopropyl or phthalimidoethyl; Y1=Y3 = phthalimidopropyl, Y2=Y4 = H; Y1=Y2 = H, Y3=Y4 = phthalimidopropyl] were reported, as well as their photophys. properties. The microwave (MW)-assisted alkylations drastically reduced the reaction times (from days to less than 45 min) and produced higher yields of both 1,3-di-substituted phthalimides I [Y1=Y3 = phthalimidoethyl; Y2=Y4 = H, Y1=Y3 = phthalimidopropyl; Y2=Y4 = H] with higher selectivity. Ball milling did not revealed to be a good method for this kind of reaction. The experimental process involved the reaction of 2-(2-Bromoethyl)isoindoline-1,3-dione(cas: 574-98-1).Product Details of 574-98-1

The Article related to dihomooxacalixarene bromolalkyl phthalimide alkylation microwave, phthalimidoalkoxy dihomooxacalixarene preparation crystal structure, nmr spectroscopy, x-ray diffraction, ball milling, conventional synthesis, dihomooxacalix[4]arenes, electronic absorption and fluorescence studies, microwave irradiation, phthalimide derivatives and other aspects.Product Details of 574-98-1

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On November 28, 2019, Takeda, Shigemitsu; Shirahase, Hiroaki; Takashima, Shunsuke; Kitao, Tatsuya published a patent.Synthetic Route of 1160653-94-0 The title of the patent was Preparation of 2H-10-oxa-2-azaanthracene-1,9-dione derivatives as readthrough inducers for premature termination codons and pharmaceutical use thereof. And the patent contained the following:

The present invention pertains to the 2H-10-oxa-2-azaanthracene-1,9-dione compounds (1,2-dihydro-10H-pyrido[4,3-b]chromene-1,10-dione derivatives) represented by general formula I [R1 = (un)substituted ring group; R2 = each (un)substituted C1-6 alkyl, C3-6 cycloalkyl, or C3-8 cycloalkenyl; R3, R4, R5 = each independently H, halo, cyano, hydroxy, or each (un)substituted acyl, NH2, C1-6 alkyl, C1-6 alkoxy, heterocyclyl, or heterocyclyloxy; or R3 and R4 or R4 and R5 are bonded to each other to form each (un)substituted C5-7 cycloalkene or 5- to 7-membered monocyclic nonaromatic heterocyclic ring together with the carbon atoms to which they are bonded]. A pharmaceutical composition containing the compound I or its pharmaceutically acceptable salt as an active ingredient, a readthrough inducer for premature termination codons containing the compound I or its pharmaceutically acceptable salt, and a prophylactic or therapeutic agent containing the compound I or its pharmaceutically acceptable salt as an active ingredient for nonsense mutation genetic disorder are also provided. The nonsense mutation genetic disorder is mucopolysaccharidosis, muscular dystrophy, Duchenne muscular dystrophy, cystic fibrosis, ceroid lipofuscinosis or Niemann-Pick disease. The compounds I or pharmaceutically acceptable salt thereof have readthrough activity for the nonsense mutation that results in premature termination codons, enable the production of full-length proteins, and are useful for the prevention or treatment of the nonsense mutation genetic disorder described above. Thus, 6-cyclobutyl-2-oxo-1-phenyl-1,2-dihydropyridin-4-yl 2-fluorobenzoate was esterified by 2-fluorobenzoyl chloride in the presence of Et3N in toluene at room temperature fro 40 min to quant. give 6-cyclobutyl-2-oxo-1-phenyl-1,2-dihydropyridin-4-yl 2-fluorobenzoate which underwent cyclization by treatment with KCN, Et3N, and 18-crown-6 in toluene at 50° for 4 h to give 43% 3-cyclobutyl-2-phenyl-2H-10-oxa-2-azaanthracene-1,9-dione (II). II at 3 μM increased the activity of α-L-iduronidase 1.5 to -10-times in Hurler syndrome patient-derived fibroblast possessing α-L-iduronidase W402X-mutation. The experimental process involved the reaction of 3-Bromo-2-fluoro-6-methoxybenzaldehyde(cas: 1160653-94-0).Synthetic Route of 1160653-94-0

The Article related to nonsense mutation genetic disorder prevention treatment oxaazaanthracenedione preparation, dihydropyridochromenedione oxaazaanthracenedione preparation readthrough inducer premature termination codon, mucopolysaccharidosis muscular dystrophy prevention treatment, duchenne muscular dystrophy cystic fibrosis prevention treatment and other aspects.Synthetic Route of 1160653-94-0

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On July 7, 2021, Zhang, Shuai; Xiao, Jun-Zhao; Li, Yan-Bo; Shi, Chang-Yun; Yin, Liang published an article.Synthetic Route of 2567-29-5 The title of the article was Copper(I)-Catalyzed Asymmetric Alkylation of Unsymmetrical Secondary Phosphines. And the article contained the following:

A Cu(I)-catalyzed asym. alkylation of HPAr1Ar2 with alkyl halides is uncovered, which provides an array of P-stereogenic phosphines in generally high yield and enantioselectivity. The electrophilic alkyl halides enjoy a broad substrate scope, including allyl bromides, propargyl bromide, benzyl bromides, and alkyl iodides. Also, 11 unsym. diarylphosphines (HPAr1Ar2) serve as competent pronucleophiles. The present methodol. is also successfully applied to catalytic asym. double and triple alkylation, and the corresponding products were obtained in moderate diastereo- and excellent enantioselectivities. Some 31P NMR experiments indicate that bulky HPPhMes exhibits weak competitively coordinating ability to the Cu(I)-bisphosphine complex, and thus the presence of stoichiometric HPAr1Ar2 does not affect the enantioselectivity significantly. Therefore, the high enantioselectivity in this reaction is attributed to the high performance of the unique Cu(I)-(R,RP)-TANIAPHOS complex in asym. induction. Finally, one monophosphine and two bisphosphines prepared by the present reaction are employed as efficient chiral ligands to afford three structurally diversified Cu(I) complexes, which demonstrates the synthetic utility of the present methodol. The experimental process involved the reaction of 4-(Bromomethyl)-1,1′-biphenyl(cas: 2567-29-5).Synthetic Route of 2567-29-5

The Article related to chiral benzyldiarylphosphine sulfide preparation crystal structure, crystal structure chiral benzyldiarylphosphine sulfide bisphosphine copper bridging halide, mol structure chiral benzyldiarylphosphine sulfide bisphosphine copper bridging halide, bisphosphine copper bridging halide cage complex preparation crystal structure and other aspects.Synthetic Route of 2567-29-5

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On December 10, 2009, Fukuoka, Masayoshi; Yokogawa, Tatsushi; Miyahara, Seiji; Miyakoshi, Hitoshi; Yano, Wakako; Taguchi, Junko; Takao, Yayoi published a patent.Application of 1187931-17-4 The title of the patent was Preparation of novel uracil compounds having inhibitory activity on human deoxyuridine triphosphatase or salts thereof. And the patent contained the following:

There are disclosed uracil compounds or salts thereof which have an excellent inhibitory activity on human deoxyuridine triphosphatase (dUTPase) and are useful as therapeutic agents for treating diseases caused by dUTPase, e.g. as anti-tumor agents. There are specifically disclosed uracil compounds represented by general formula [I; n = 1-3 integer; X = a bond, O, S, C2-6 alkenylene, (un)substituted divalent aromatic hydrocarbon group, (un)substituted and (un)saturated divalent heterocyclic group; Y = a bond, C1-8 linear or branched alkylene optionally having cycloalkylidene structure on one of the carbon atoms; Z = SO2NR1R2, NR3SO2R4; R1, R2 = C1-6 alkyl, (un)substituted aralkyl wherein in case where the aromatic hydrocarbon group of the aralkyl is Ph, the Ph and its substituents together form a condensed bicyclic hydrocarbon group; or NR1R2 form (un)substituted saturated heterocyclic ring; R3 = H, C1-6 alkyl; R4 = each (un)substituted aromatic hydrocarbon group or unsaturated heterocyclic group] or salts thereof. Thus, 6.8 g N-(3-(cyclopropylmethoxy)benzyl)-3-(methoxymethoxy)propane-1-sulfonamide was dissolved in 20 mL CH2Cl2, treated with a solution of 6.7 mL 1.0 M BCl3/CH2Cl2 at 0°, stirred at room temperature for 1.5 h, concentrated under reduced pressure, redissolved in 25 mL CH2Cl2, treated with a solution of 7.1 g 2,4-bis(trimethylsilyloxy)pyrimidine in 150 mL CH2Cl2 and 180 mg iodine, and heated at reflux for 95° for 3.5 h to give, after workup and silica gel chromatog., 42% N-(3-(cyclopropylmethoxy)benzyl)-3-((2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methoxy)propane-1-sulfonamide (II). II and (R)-N-(1-(3-(cyclopropylmethoxy)-4-fluorophenyl)propyl)-3-((2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methoxy)propane-1-sulfonamide (III) showed IC50 of 0.33 and 0.03 μM, resp., against human deoxyuridine triphosphatase. The experimental process involved the reaction of (R)-1-(2-Bromophenyl)ethanamine hydrochloride(cas: 1187931-17-4).Application of 1187931-17-4

The Article related to antitumor uracil derivative preparation, sulfonamide containing uracil derivative preparation inhibitor human deoxyuridine triphosphatase, uracil derivative preparation inhibitor human deoxyuridine triphosphatase, dioxodihydropyrimidinylmethoxypropanesulfonamide preparation inhibitor human deoxyuridine triphosphatase and other aspects.Application of 1187931-17-4

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On July 22, 1999, Stolle, Andreas; Antonicek, Horst-Peter; Lensky, Stephen; Voerste, Arnd; Muller, Thomas; Baumgarten, Jorg; Von Dem Bruch, Karsten; Muller, Gerhard; Stropp, Udo; Horvath, Ervin; De Vry, Jean-Marie Viktor; Schreiber, Rudy published a patent.SDS of cas: 259231-26-0 The title of the patent was Preparation of 6-benzyl-5-methylidenehexahydrocyclopenta[c]furan-1-ones as metabotropic glutamate receptor modulators.. And the patent contained the following:

Title compounds [I; A = CH2, CO, CR4OH, (CH2)aCHR5, alkylene, alkenylene, alkynylene; a = 0-4; R4 = H, alkyl; R5 = Ph; R1 = H, (substituted) cycloalkyl, heterocyclyl, benzoheterocyclyl, aryl, etc.; R2, R3 = H, alkyl; DE = CH2C(:CR32R31)CH2, CR33:CR34CHR35, etc.; R31-R35 = H, Ph, alkyl], were prepared for preventing and/or treating diseases caused by the hyper- or hypofunction of the glutamatergic system, especially cerebral ischemia, cranial/cerebral trauma, pain or CNS-mediated cramps (no data). Thus, 2-methoxycarbonyl-4-methylidenecyclopentanecarboxylic acid in THF at -15° was treated with Et3n and EtO2CCl followed by 1 h stirring at room temperature The mixture was filtered and the filtrate in MeOH at -15° was treated with NaBH4 followed by 1 h stirring at room temperature to give 58% (3aS*,6aR*)-5-methylidenehexahydrocyclopenta[c]furan-1-one. The latter in PhMe was was added to LiN(SiMe3)2 in THF/PhMe at -78° followed by warming to room temperature, 1 h stirring, and addition of PhCH2Br to give 68% (3aS*,6aR*)-6a-benzyl-5-methylidenehexahydrocyclopenta[c]furan-1-one. The experimental process involved the reaction of 2-Bromo-4-(bromomethyl)-1-methylbenzene(cas: 259231-26-0).SDS of cas: 259231-26-0

The Article related to benzylmethylidenehexahydrocyclopentafuranone preparation metabotropic glutamate receptor modulator, cyclopentafuranone benzyl methylidene preparation metabotropic glutamate receptor modulator, analgesic benzylmethylidenehexahydrocyclopentafuranone, head trauma treatment benzylmethylidenehexahydrocyclopentafuranone and other aspects.SDS of cas: 259231-26-0

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

Turksoy, Abdurrahman; Scattolin, Thomas; Bouayad-Gervais, Samir; Schoenebeck, Franziska published an article in 2020, the title of the article was Facile Access to AgOCF3 and Its New Applications as a Reservoir for OCF2 for the Direct Synthesis of N-CF3, Aryl or Alkyl Carbamoyl Fluorides.Safety of 4-(Bromomethyl)-1,1′-biphenyl And the article contains the following content:

Herein, a straightforward and quant. strategy for the preparation of valuable AgOCF3 at room temperature and showcase its performance in trifluoromethoxylations or as reservoir for O=CF2 was showed. This enabled the direct, practical and safe synthesis of valuable N-alkyl/aryl carbamoyl fluorides and N-CF3 carbamoyl fluorides from secondary amines and isothiocyanides, resp. Mechanistic data indicated that AgOCF3 does not liberate O=CF2 until it was activated by a nucleophilic co-reagent, reinforcing the stability of the salt under new preparation strategy. The experimental process involved the reaction of 4-(Bromomethyl)-1,1′-biphenyl(cas: 2567-29-5).Safety of 4-(Bromomethyl)-1,1′-biphenyl

The Article related to silver trifluoromethoxide green preparation, trifluoromethyl ether preparation, alkyl halide silver trifluoromethoxide substitution, alc alkyl silver trifluoromethoxide dehydrotrifluoromethoxylation, carbamoyl fluoride preparation, n-trifluoromethyl, carbamoyl fluorides, fluorination, mechanism, synthetic methods and other aspects.Safety of 4-(Bromomethyl)-1,1′-biphenyl

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On April 14, 2022, Kuduk, Scott; Pietsch, Eva Christine; Guttke, Christina D.; Bush, Tammy L. published a patent.Related Products of 1003709-39-4 The title of the patent was Preparation of substituted isoquinolinones as dihydroorotate dehydrogenase inhibitors for use in combinations with hypomethylating agents. And the patent contained the following:

Disclosed are methods of treating a subject who has been diagnosed with a disease, syndrome, condition, or disorder affected by DHODH enzymic activity comprising administering: a therapeutically effective amount of a DHODH inhibitor I [X = CH or N; Y = CH or N; R1 = (un)substituted alkyl, haloalkyl, cycloalkyl, etc.; R2 = II (wherein Ra = alkyl, haloalkyl, cycloalkyl; Rb = (un)substituted alkyl); R3 = H, halo, Me and OMe; R4 = (un)substituted alkyl, cycloalkyl, pyridyl, etc.], a therapeutically effective amount of a hypomethylating agent and optionally, a therapeutically effective amount of a BCL-2 inhibitor. E.g., a multi-step synthesis of III, starting from Et 2-(benzyloxy)acetate and hydrazine hydrate, was described. The latter was assessed for its ability to induce cytotoxicity in 30 primary AMF patient samples by Cell TiterGlo assay. Eighteen of the AMF samples were highly sensitive to the compound III resulting in IC50 values between 0.11 and 95.1 nM, one patient sample had an IC50 value of 469.1 nM and the remaining 11 cases demonstrated little sensitivity to III with the highest concentration evaluated (3000 nM) unable to kill more than 50% of the tumor cells. The experimental process involved the reaction of 2-Bromo-4-fluoro-5-methylbenzoic acid(cas: 1003709-39-4).Related Products of 1003709-39-4

The Article related to isoquinolinone preparation dihydroorotate dehydrogenase inhibitor combination chemotherapy hypomethylating agent, dhodh inhibitor combination chemotherapy hypomethylating agent isoquinolinone preparation, combination chemotherapy dhodh bcl2 inhibitor hypomethylating agent isoquinolinone preparation and other aspects.Related Products of 1003709-39-4

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary